Christopher M. Cashman is Chairman of the Board and Chief Executive Officer of Marinus. Chris is a recognized leader in the biopharmaceutical industry and has decades of experience leading life sciences companies. Before joining Marinus, Chris was co-founder, President and CEO of Protez Pharmaceuticals, Inc., a company specializing in the development of antibiotics, which was acquired by Novartis. Prior to his time with Protez, Chris was President and CEO of Message Pharmaceuticals, Inc., and held various leadership roles at both Pfizer, Inc., and SmithKline Beecham plc. Chris currently serves on the Board of Directors of Rapid Micro Biosystems, Inc., Noble Biomaterials, Inc., and MBF Therapeutics, Inc. Chris holds an M.S. in economics from Purdue University and B.S. in business management from the University of Minnesota.
Edward F. Smith is Vice President, Chief Financial Officer, Secretary and Treasurer of Marinus. Ed has 15 years of experience in raising capital, operating, and providing financial oversight to publicly traded biotechnology companies. Before joining Marinus, Ed served as CFO of PolyMedix, Inc., a publicly traded biotechnology company developing small-molecule drugs for infectious diseases. Prior to PolyMedix, Ed was Executive Director of Finance at InKine Pharmaceutical Company, Inc., a NASDAQ listed biotechnology company acquired by Salix Pharmaceuticals, Inc. Earlier in his career, Ed held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte & Touche, LLP. Mr. Smith was licensed as a Certified Public Accountant in Pennsylvania and holds a B.S. in business administration from the University of Hartford.
Dr. Lappalainen has 10 years of experience in the design, monitoring, interpretation and reporting of clinical trials at pharmaceutical research and development companies, including AstraZeneca. He is a U.S. board certified psychiatrist with extensive experience in clinical practice and medical research. Most recently, he served as Executive Director, Drug Development Services at Premier Research CRO, where he oversaw the safety and medical monitoring of clinical trials and provided consultations on clinical trial design and drug development. Prior to Premier Research, Dr. Lappalainen held various clinical development positions at AstraZeneca. While at AstraZeneca, he served as the Global Lead Physician for the MOVANTIK™ (naloxegol) Phase 3 program in non-cancer pain and opioid induced constipation and the Lead Physician for the early clinical development of two GABAA sub-type selective molecules. Earlier in his career, Dr. Lappalainen served as an Assistant Professor, Clinical Director and Attending Physician at Yale University School of Medicine, Department of Psychiatry.
Executive Director, Investor & Strategic Relations
Marinus Pharmaceuticals, Inc.